<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.109324</article-id><article-id pub-id-type="publisher-id">ACM-37803</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200900000_68271165.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  非酒精性脂肪性肝病相关肝纤维化研究进展
  Advances in the Study of Fibrosis Associated with Nonalcoholic Fatty Liver Disease
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>宋</surname><given-names>清莲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>戴</surname><given-names>光荣</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>09</month><year>2020</year></pub-date><volume>10</volume><issue>09</issue><fpage>2155</fpage><lpage>2157</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    随着人们生活水平的提高，在全球范围内，非酒精性脂肪性肝病的发病率呈逐年上升趋势，而非酒精性脂肪性肝炎是疾病进展的主要驱动力，是肝脏相关病变结果的重要预后因素。为此早期诊断非酒精性脂肪性肝炎和准确评估肝纤维化的严重程度对于治疗策略、治疗反应、判断预后是至关重要的。然而，目前对于非酒精性脂肪性肝炎的无创诊断方法仍是临床医师面临的一大困境。本文将根据最新研究进展，对现有的无创诊断方法进行阐述。
    With the improvement of people’s living standard, the incidence of non-alcoholic fatty liver disease is on the rise year by year globally. Non-alcoholic steatohepatitis is the main driving force of the disease progression and an important prognostic factor for the outcome of liver-related lesions. For this reason, early diagnosis of nonalcoholic steatohepatitis and accurate assessment of the severity of liver fibrosis are crucial for treatment strategy, treatment response, and prognosis. However, noninvasive diagnostic methods for nonalcoholic steatohepatitis remain a major dilemma for clinicians. In this paper, based on the latest research progress, the existing non-invasive diagnostic methods are described. 
  
 
</p></abstract><kwd-group><kwd>非酒精性脂肪性肝病，非酒精性脂肪性肝炎，肝纤维化, Non-Alcoholic Fatty Liver Disease</kwd><kwd> Nonalcoholic Steatohepatitis</kwd><kwd> Liver Fibrosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>随着人们生活水平的提高，在全球范围内，非酒精性脂肪性肝病的发病率呈逐年上升趋势，而非酒精性脂肪性肝炎是疾病进展的主要驱动力，是肝脏相关病变结果的重要预后因素。为此早期诊断非酒精性脂肪性肝炎和准确评估肝纤维化的严重程度对于治疗策略、治疗反应、判断预后是至关重要的。然而，目前对于非酒精性脂肪性肝炎的无创诊断方法仍是临床医师面临的一大困境。本文将根据最新研究进展，对现有的无创诊断方法进行阐述。</p></sec><sec id="s2"><title>关键词</title><p>非酒精性脂肪性肝病，非酒精性脂肪性肝炎，肝纤维化</p></sec><sec id="s3"><title>Advances in the Study of Fibrosis Associated with Nonalcoholic Fatty Liver Disease</title><p>Qinglian Song<sup>*</sup>, Guangrong Dai<sup>#</sup></p><p>Affiliated Hospital of Yan’an University, Yan’an Shaanxi</p><p><img src="//html.hanspub.org/file/44-1571585x4_hanspub.png" /></p><p>Received: Sep. 2<sup>nd</sup>, 2020; accepted: Sep. 17<sup>th</sup>, 2020; published: Sep. 24<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/44-1571585x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>With the improvement of people’s living standard, the incidence of non-alcoholic fatty liver disease is on the rise year by year globally. Non-alcoholic steatohepatitis is the main driving force of the disease progression and an important prognostic factor for the outcome of liver-related lesions. For this reason, early diagnosis of nonalcoholic steatohepatitis and accurate assessment of the severity of liver fibrosis are crucial for treatment strategy, treatment response, and prognosis. However, noninvasive diagnostic methods for nonalcoholic steatohepatitis remain a major dilemma for clinicians. In this paper, based on the latest research progress, the existing non-invasive diagnostic methods are described.</p><p>Keywords:Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Liver Fibrosis</p><disp-formula id="hanspub.37803-formula42"><graphic xlink:href="//html.hanspub.org/file/44-1571585x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/44-1571585x8_hanspub.png" /> <img src="//html.hanspub.org/file/44-1571585x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>非酒精性脂肪性肝病(NAFLD)逐渐成为全球常见慢性肝病的主要疾病之一。它不仅导致肝脏本身病变，而且对肝外脏器(如心脏、肾脏、胰腺等)也有影响 [<xref ref-type="bibr" rid="hanspub.37803-ref1">1</xref>]。因此，了解其发病机制、疾病特征、演变过程以及诊断方法是提高NAFLD诊治的关键。目前诊断非酒精性脂肪性肝炎的金标准仍然是肝组织穿刺活检术，因其是有创检查且肝脏纤维化的不均匀分布常导致组织学评判错误，故在临床上是受限的。近年来，学者们通过潜在的发病机制不断寻求一些无创方法评估肝纤维化来代替肝组织活检。这些无创检查包括血清生化指标，影像学检查。本文将对这些无创检查方法进行简要阐述以寻求较理想的诊断方法。</p><p>预测NASH的发生与纤维化程度目前有好多种血清学标志物，如血清酶学(ALT、AST)炎性细胞因子(IL-6、超敏C反应蛋白)，细胞凋亡相关因子(CK18-M30、CK18M-65)，脂肪组织代谢产物；但近年来也逐渐发展起一些新型的检测方法，包括基因组学，分子组学以及蛋白组学等。</p></sec><sec id="s6"><title>2. 紫藤凝集素阳性的Mac-2结合蛋白</title><p>Mac-2结合蛋白(Mac-2 binding protein，Mac-2BP)是一种N型糖基化蛋白，在正常肝脏中几乎检测不到，随着纤维化的进展，在损伤肝细胞中比较容易检测到。它主要参与宿主免疫防御，首次在人乳腺癌细胞中提取得到 [<xref ref-type="bibr" rid="hanspub.37803-ref2">2</xref>]。现已被用作多种癌症如肝癌、前列腺癌、肺癌等血清生物标志物。相关研究表明Mac-2BP与其配体90k结合通过宿主免疫激活自然杀伤细胞，从而在细胞防御中起报警信号。植物凝集素是一种具有识别糖链结构的糖结合活性蛋白，紫藤凝集素(Wisteria floribunda agglutinin, WFA)是在紫藤中提取的主要凝集素之一 [<xref ref-type="bibr" rid="hanspub.37803-ref3">3</xref>]。WFA能与Mac-2bp结合形成紫藤凝集素阳性的巨噬细胞-2结合蛋白(WFA-positive Mac-2-binding protein, WFA + −M2BP)。Kiyoaki Ito等 [<xref ref-type="bibr" rid="hanspub.37803-ref4">4</xref>] 通过对21项研究共涉及4772名患者的荟萃分析表明WFA + −M2BP预测肝显著纤维化(≥F2)、晚期纤维化(≥F3)肝硬化(=F4)的敏感性和特异性分别为0.69、0.778、0.764和0.758、0.818、0.839，其中在NASH (≥F2) VS (≥F3) VS (=F4)中平均敏感度分别为0.472 (95%CI, 0.379~0.567) VS 0.737 (95%CI, 0.576~0.858) VS 0.692 (95%CI, 0.409~0.879)，平均特异度分别为0.786 (95%CI, 0.598~0.901) VS 0.802 (95%CI, 0.710~0.870) VS 0.884 (95%CI, 0.814~0.930)。</p><p>此外，Pavel Strnad等 [<xref ref-type="bibr" rid="hanspub.37803-ref5">5</xref>] 对198名经肝组织穿刺活检确诊的NASH患者进行血清WFA + −M2BP检测发现与健康对照组相比，纤维化非酒精性脂肪肝和非酒精性脂肪肝肝硬化血清WFA + −M2BP水平明显增加(P &lt; 0.001)，尤为重要的是，血清WFA + −M2BP水平与炎症中度相关，与纤维化分期密切相关[相关系数为0.61，(95%CI, 0.52~0.69)，且P &lt; 0.001]。Hiroki等 [<xref ref-type="bibr" rid="hanspub.37803-ref5">5</xref>] 研究再次证实了血清WFA + −M2BP水平与NASH纤维化有关。由此可见WFA + −M2BP是一种新型的有前景的糖蛋白组学标志物，可用于晚期肝纤维化的预测。它将有助于临床试验对患者的危险分层，并将有可能在未来取代肝活检。</p></sec><sec id="s7"><title>3. 肝脏芯片模型</title><p>肝脏脂肪病变动物模型实验在一定程度上受到了限制，因此为了解决这一问题人们不断探索发现了新的体外实验模型，而这些体外模型必须满足以下条件：其一，可复制肝脏的复杂结构及相关细胞的代谢功能；其二，合理的模型生理设计参数；其三，通过相似的机制模拟应对体内的炎症反应；故研究者们根据这些条件开发了3D模型即肝脏芯片模型。</p><p>肝脏芯片是一个3D体外肝脏微生理系统 [<xref ref-type="bibr" rid="hanspub.37803-ref6">6</xref>]，旨在模拟原始肝脏结构、特定的微环境以及微流体系统以模拟肝脏正常生理功能的3D细胞培养表示的微型组织和器官。肝球体是一种常见的研究肝脏的体外模型 [<xref ref-type="bibr" rid="hanspub.37803-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.37803-ref8">8</xref>]，其可模拟肝脏天然的结构和功能，可诱发肝脏脂肪堆积和胶原沉积。NAFLD模型是基于脂肪酸代谢来模拟实现的 [<xref ref-type="bibr" rid="hanspub.37803-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.37803-ref10">10</xref>]。其方法可能为在装置内使用脂肪酸来诱导原代人肝细胞，使细胞内出现甘油三酯积累、细胞色素P4502E1等关键基因上调，产生肝纤维化、炎症等相关蛋白表达。我们可以通过测定相关蛋白的含量来推测肝脏纤维化程度。最新研究表明 [<xref ref-type="bibr" rid="hanspub.37803-ref11">11</xref>]，Kim等发现肝脏芯片可用于研究乳腺癌继发性肝脏转移。虽然肝脏芯片模型尚处于早期发展阶段，但它为未来其他肝病模型奠定了一定的基础，相信在不久的将来是一种有着非常广阔的应用前景模型。</p></sec><sec id="s8"><title>4. 研究展望</title><p>肝脏慢性炎症是肝病进展的关键，其可进一步发展至纤维化、肝硬化甚至肝癌，由于早期纤维化尚可逆转，故提高检测早期肝脏纤维化是临床医师所面临的一大困境。本文阐述的肝脏芯片是一种新型体外天然肝脏模型，是未来研究肝病的较理想模型，目前相关研究甚少，仍需投入大量试验来进一步验证。</p></sec><sec id="s9"><title>文章引用</title><p>宋清莲,戴光荣. 非酒精性脂肪性肝病相关肝纤维化研究进展Advances in the Study of Fibrosis Associated with Nonalcoholic Fatty Liver Disease[J]. 临床医学进展, 2020, 10(09): 2155-2157. https://doi.org/10.12677/ACM.2020.109324</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.37803-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">宋清莲, 谭玉娥, 刘京京, 袁贝贝, 李敏, 贺礼琴, 戴光荣. 非酒精性脂肪性肝炎大鼠模型的建立及其胰腺, 肾脏的组织学病理变化[J]. 临床肝胆病杂志, 2020, 36(1): 140-144.</mixed-citation></ref><ref id="hanspub.37803-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Toshima, T., Shirabe, K., Ikeqami, T., et al. (2014) A Novel Serum Marker, Glycosylated Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein (WFA+ -M2BP), for Assessing Liver Fibrosis. Gastroenterology, 50, 76-84.  
://doi.org/10.1007/s00535-014-0946-y</mixed-citation></ref><ref id="hanspub.37803-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">陈凡, 陈海芳, 傅俊. 紫藤凝集素的分离纯化及理化性质研究[J]. 植物科学学报, 1994, 12(3): 270-276.</mixed-citation></ref><ref id="hanspub.37803-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Ito, K., Murotani, K., Nakade, Y., et al. (2017) Serum WFA+-M2BP Levels Predict Liver Fibrosis, Development of Hepatocellular Carcinoma, and Overall Survival: A Meta-Analysis. Journal of Gastroenterology &amp; Hepatology, 32, 1922-1930.  
://doi.org/10.1111/jgh.13802</mixed-citation></ref><ref id="hanspub.37803-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Naim, A., Casey, J., Leon, A., et al. (2018) Serum Wisteria Floribunda Agglutinin-Positive Mac-2-Binding Protein Levels Predict the Presence of Fibrotic Nonalcoholic Steatohepatitis (NASH) and NASH Cirrhosis. PLoS ONE, 13, e0202226. ://doi.org/10.1371/journal.pone.0202226</mixed-citation></ref><ref id="hanspub.37803-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Elena, B.A., Mihai, B.P., Stanca, M.C., et al. (2020) Microfluidic Endothelium-on-a-Chip Development, from in Vivo to in Vitro Experimental Models. Romanian Journal of Morphology and Embryology, 61, 15-23.  
://doi.org/10.47162/RJME.61.1.02</mixed-citation></ref><ref id="hanspub.37803-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, Y., Shi, Q., Peng, Q., et al. (2019) A Simplified 3D Liver Microsphere Tissue Culture Model for Hepatic Cell Signaling and Drug-Induced Hepatotoxicity Studies. International Journal of Molecular Medicine, 44, 121-125.  
://doi.org/10.3892/ijmm.2019.4321</mixed-citation></ref><ref id="hanspub.37803-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">A E M , B J F , A S H . (2020) Microfluidic Organ-on-a-Chip Models of Human Liver Tissue. Acta Biomaterialia, 52, 160-167.</mixed-citation></ref><ref id="hanspub.37803-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Manuele, G., Maria, G.S., Andrea, Z., et al. (2020) Quercetin and Hydroxytyrosol as Modulators of Hepatic Steatosis: A NAFLD-on-a-Chip Study. Biotechnology and Bioengineering. ://doi.org/10.1002/bit.27557</mixed-citation></ref><ref id="hanspub.37803-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Soufian, L., Kim, H.-J., Lee, K.J., et al. (2019) A Human Liver-on-a-Chip Platform for Modeling Nonalcoholic Fatty Liver Disease. Advanced Biosystems, 3, e1900104. ://doi.org/10.1002/adbi.201900104</mixed-citation></ref><ref id="hanspub.37803-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Kim, J., Lee, C., Kim, I., et al. (2020) Three-Dimensional Human Liver-Chip Emulating Premetastatic Niche Formation by Breast Cancer-Derived Extracellular Vesicles. ACS Nano. ://doi.org/10.1021/acsnano.0c04778</mixed-citation></ref></ref-list></back></article>